Synthesis of CpFe(CO)(L) complexes of hydantoin anions (Cp = eta5-C5H5, L = CO, PPh3), and the use of the 5,5-diphenylhydantoin anion complexes as tracers in the nonisotopic immunoassay CMIA of this antiepileptic drug.
As part of our ongoing development of the CMIA nonisotopic immunoassay method, in which the tracers are metal carbonyl complexes and detection is by Fourier transform infrared spectroscopy, we examined the potential use as tracers of the complexes CpFe(CO)2(5,5-diphenylhydantoin) 2d and CpFe(CO)(PPh3)(5, 5-diphenylhydantoin) 3. The present study involved the synthesis of a series of hydantoin complexes (2a-2d), in particular that of the derivative of 5,5-diphenylhydantoin 2d. The structure of 2d was confirmed by X-ray crystallography. The infrared analysis, establishing the position and intensity of the characteristic metal-carbonyl peaks of complexes 2d and 3 in the 1850-2200 cm-1 region, shows that measurement of the absorbance values of these characteristic peaks will permit quantitative analysis in the picomole range, the norm for routine use in immunoassay and thus suitable for use as CMIA tracers. Cross-reaction rates of these tracers with anti-DPH specific antibodies show that 2d and 3 are both recognized by anti-DPH antibodies (cross-reaction rates 43 and 20%, respectively). In developing a CMIA of DPH with these tracers, it was found that 3, with a single, intense band at 1977 cm-1, had very promising IR characteristics for use in multiassay CMIA, but probably owing to its relatively weak affinity for the antibodies, it was not possible to develop a CMIA for DPH using this tracer. Complex 2d, however, showed better recognition by the antibodies, and using this complex as a tracer, it was possible to develop a particularly sensitive monoassay of DPH by the CMIA method.
Vessières
A
A
Ecole Nationale Supérieure de Chimie de Paris, Laboratoire de Chimie Organométallique, UMR CNRS 7576, 11, rue Pierre et Marie Curie, 75231 Paris Cedex 05, France.
Kowalski
K
K
Zakrzewski
J
J
Stepien
A
A
Grabowski
M
M
Jaouen
G
G
D000838:Anions; D000915:Antibody Affinity; D000918:Antibody Specificity; D000927:Anticonvulsants / Q000032:analysis / Q000737:chemistry* / Q000276:immunology; D003429:Cross Reactions; D018360:Crystallography, X-Ray; D003517:Cyclopentanes / Q000737:chemistry; D005544:Forecasting; D005583:Fourier Analysis; D006827:Hydantoins / Q000737:chemistry*; D007118:Immunoassay / Q000379:methods*; D007202:Indicators and Reagents; D058085:Iron Compounds / Q000737:chemistry*; D009942:Organometallic Compounds / Q000737:chemistry*; D010672:Phenytoin / Q000032:analysis / Q000737:chemistry* / Q000276:immunology; D013055:Spectrophotometry, Infrared
D000838:Anions; D000927:Anticonvulsants; D003517:Cyclopentanes; D006827:Hydantoins; D007202:Indicators and Reagents; D058085:Iron Compounds; D009942:Organometallic Compounds; D010672:Phenytoin